Ratings Orion Oyj Nasdaq Helsinki

Equities

ORNAV

FI0009014369

Market Closed - Nasdaq Helsinki Other stock markets 08:59:41 07/06/2024 pm IST			5-day change	1st Jan Change
38.8 ^EUR	+0.13%		+1.84%	-1.02%

03/06	Orion Partners with Universities for Biotechnology Project in Finland	MT
07/05	Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
The company is in a robust financial situation considering its net cash and margin position.
The company is one of the best yield companies with high dividend expectations.
Over the last twelve months, the sales forecast has been frequently revised upwards.

Weaknesses

The firm trades with high earnings multiples: 22.63 times its 2024 earnings per share.
The company's enterprise value to sales, at 3.94 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ORION OYJ	-1.02%	5.91B	-
ELI LILLY AND COMPANY	+45.82%	765B	C+
NOVO NORDISK A/S	+40.95%	632B	B
JOHNSON & JOHNSON	-6.16%	354B	C+
MERCK & CO., INC.	+19.86%	331B	B-
ABBVIE INC.	+9.32%	299B	C+
ASTRAZENECA PLC	+18.45%	248B	B+
ROCHE HOLDING AG	-0.78%	219B	A+
NOVARTIS AG	+11.88%	216B	B-
AMGEN INC.	+5.90%	164B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes